A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2015
At a glance
- Drugs MK 2206 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 12 Jun 2013 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 09 Nov 2012 Planned End Date changed from 1 Aug 2011 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 16 Dec 2010 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center)